Blog: Affordable Care Act
April 1, 2015 | Affordable Care Act, USA
What does the future hold for the US pharma industry?
Everywhere you go in the States, you hear talk of the Affordable Care Act, also known as ObamaCare. In essence, the ACA is designed to broaden coverage to the millions of Americans who have not had healthcare in the past due to not being employed or just not being able to afford it. ACA had a rocky time getting passed into law and now that it has launched on January 1, 2014, things are not getting much easier. After the President promised that no one who likes his/her doctor would have to switch doctors, some folks are being dropped by their insurance and do have to leave their doctors. Younger people almost certainly have to pay more than they have been paying for coverage because the way the new system is structured, younger, healthier people are underwriting the costs for older people who utilize the healthcare system more frequently (and at greater cost). At the core of the debate is a values questions: some people truly believe that everyone should have access to the healthcare system as provided by the ACA. Others exude a really American spirit of not wanting any government intervention or interference in their lives. So despite the fact that this program might be advantageous to many, it represents an intrusion. This disagreement is unlikely to be easily resolved as it is a core values question.
It has been almost a given that full time employees offer some level of healthcare coverage to employees and some employers are taking advantage of this shift in the landscape to divorce employment from healthcare benefits and force their employees to shop independently for coverage on the newly created exchanges. In fact, this has happened to my own husband. So this represents added expense to the employees, unless the employers decide to underwrite the cost in some way (which has yet to be determined). This is “a great unknown” and something that will be determined company to company, not on a national level.
There are some facts that are emerging, although the system is still unfolding. Some folks will have to change physicians and physicians will have to see more patients, possibly at a lower reimbursement rate than before. The rates themselves are still unclear and may not be clear for quite some time. The system is structured so that everyone will have access to care; in fact, everyone must have access to care. That means that there are financial penalties if people don’t sign up.
So everyone is a bit at sea. Pharma companies, too are wondering about the impact of the ACA on their worlds. What guidelines will physicians have to follow in prescribing? What tests will be covered? What types of reporting will they have do (electronic record keeping)? I spoke to my colleague from our sister company, Access Partnership about this. His idea is that things are unclear in part because, although the Supreme Court upheld the centerpiece of the Affordable Care Act more than a year ago, there are still several legal challenges to the new system, which may slow down the implementation and make it difficult to envision how the new system will play out over time.
As of right now, the Affordable Care Act is just beginning and it is difficult to see “around the next bend” as to what the long term implications will be for the interested parties (and by that I mean everyone!).
Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more here: http://bit.ly/1Pj6vu1
This content was provided by Inizio
Company Details
Latest Content from Inizio
AAD conference 2016
Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients
Video: Global Biosimilars Market
Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch
Case study: Understanding Patient Willingness to Pay in Emerging Markets
Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...
From promise to practice: immuno-oncology in action Part 3 – Emerging Markets
Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.
It’s a digital hat trick for Pegasus as it scoops GOLD and two SILVERS at the PM Society Digital Awards 2016
Pegasus received three top accolades at the PM Society Digital Media Awards 2016, including gold for the highly acclaimed Craft: Best Innovation award with Biogen’s MS Explorer, and two silvers...
What we do and who we do it for | Pegasus
We’ve built a new type of health communications consultancy. One that believes in a ‘health first, sector second’ approach. One that connects with every stakeholder. One that blends traditional, digital...
Understanding decision making in health | Pegasus
To reflect the importance of self-care in health, we developed and launched a new model for exploring personal health decision-making which provides a framework for strategic planning, whatever the therapy...
An animated approach to communicating healthy messages | Pegasus
Telling a health message is one half of the battle. Ensuring that these messages resonate is another matter entirely. The Lab is our 25-strong, in-house creative and content team within...
Pegasus shortlisted for four PM Society Digital Media Awards 2016
Pegasus, the UK’s leading independent health communications consultancy, has had recognition of its work in digital media with shortlistings for four awards at the PM Society Digital Media Awards 2016...
Infographic: HCV EU
Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.Our latest market snapshot offers an introduction...